Baidu
map

Nat Med:全基因组种系与前列腺癌表观遗传背景相关

2019-10-07 AlexYang MedSci原创

肿瘤的发生可以由种系、环境和随机因素诱发。但这些因素是怎样互作产生肿瘤的分子表型的仍旧未知。最近,有研究人员在589个局部前列腺肿瘤中量化了种系多样性对体细胞表观基因组的影响。研究发现,倾向性风险位点影响了肿瘤的表观基因组,揭示了癌症易感性的机制。研究人员总共见顶了1178个位点与肿瘤组织中甲基化的改变有关,而不是非恶性肿瘤组织。这些肿瘤甲基化数量性状位点能够影响染色质结构以及RNA和蛋白的丰度。

肿瘤的发生可以由种系、环境和随机因素诱发。但这些因素是怎样互作产生肿瘤的分子表型的仍旧未知。

最近,有研究人员在589个局部前列腺肿瘤中量化了种系多样性对体细胞表观基因组的影响。研究发现,倾向性风险位点影响了肿瘤的表观基因组,揭示了癌症易感性的机制。研究人员总共见顶了1178个位点与肿瘤组织中甲基化的改变有关,而不是非恶性肿瘤组织。这些肿瘤甲基化数量性状位点能够影响染色质结构以及RNA和蛋白的丰度。其中1个突出的肿瘤甲基化数量性状位点与AKT1表达相关,并且在发现组和验证组中确定的局部治疗后预测能够复发。

最后,研究人员指出,这些数据阐释了种系与原发性肿瘤表观基因组之间的复杂关系,也许能够帮助鉴定恶性疾病的种系生物标记,从而协助患者分类和优化侵入性或者昂贵的诊断过程。

原始出处:

Kathleen E. Houlahan, Yu-Jia Shiah, Alexander Gusev et al. Genome-wide germline correlates of the epigenetic landscape of prostate cancer. Nat Med. 07 Oct 2019

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1883907, encodeId=0420188390e14, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jan 31 07:06:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055494, encodeId=6d2b2055494ba, content=<a href='/topic/show?id=e6a495203b3' target=_blank style='color:#2F92EE;'>#遗传背景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95203, encryptionId=e6a495203b3, topicName=遗传背景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Jun 19 19:06:00 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546514, encodeId=bc4715465142a, content=<a href='/topic/show?id=81eb2939373' target=_blank style='color:#2F92EE;'>#全基因组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29393, encryptionId=81eb2939373, topicName=全基因组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc2113925052, createdName=ms1692810954239974, createdTime=Wed Oct 09 12:06:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610021, encodeId=bfae1610021dd, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Oct 09 12:06:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040563, encodeId=82cf1040563cd, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Oct 08 00:06:00 CST 2019, time=2019-10-08, status=1, ipAttribution=)]
    2020-01-31 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1883907, encodeId=0420188390e14, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jan 31 07:06:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055494, encodeId=6d2b2055494ba, content=<a href='/topic/show?id=e6a495203b3' target=_blank style='color:#2F92EE;'>#遗传背景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95203, encryptionId=e6a495203b3, topicName=遗传背景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Jun 19 19:06:00 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546514, encodeId=bc4715465142a, content=<a href='/topic/show?id=81eb2939373' target=_blank style='color:#2F92EE;'>#全基因组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29393, encryptionId=81eb2939373, topicName=全基因组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc2113925052, createdName=ms1692810954239974, createdTime=Wed Oct 09 12:06:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610021, encodeId=bfae1610021dd, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Oct 09 12:06:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040563, encodeId=82cf1040563cd, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Oct 08 00:06:00 CST 2019, time=2019-10-08, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1883907, encodeId=0420188390e14, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jan 31 07:06:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055494, encodeId=6d2b2055494ba, content=<a href='/topic/show?id=e6a495203b3' target=_blank style='color:#2F92EE;'>#遗传背景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95203, encryptionId=e6a495203b3, topicName=遗传背景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Jun 19 19:06:00 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546514, encodeId=bc4715465142a, content=<a href='/topic/show?id=81eb2939373' target=_blank style='color:#2F92EE;'>#全基因组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29393, encryptionId=81eb2939373, topicName=全基因组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc2113925052, createdName=ms1692810954239974, createdTime=Wed Oct 09 12:06:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610021, encodeId=bfae1610021dd, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Oct 09 12:06:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040563, encodeId=82cf1040563cd, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Oct 08 00:06:00 CST 2019, time=2019-10-08, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1883907, encodeId=0420188390e14, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jan 31 07:06:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055494, encodeId=6d2b2055494ba, content=<a href='/topic/show?id=e6a495203b3' target=_blank style='color:#2F92EE;'>#遗传背景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95203, encryptionId=e6a495203b3, topicName=遗传背景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Jun 19 19:06:00 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546514, encodeId=bc4715465142a, content=<a href='/topic/show?id=81eb2939373' target=_blank style='color:#2F92EE;'>#全基因组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29393, encryptionId=81eb2939373, topicName=全基因组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc2113925052, createdName=ms1692810954239974, createdTime=Wed Oct 09 12:06:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610021, encodeId=bfae1610021dd, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Oct 09 12:06:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040563, encodeId=82cf1040563cd, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Oct 08 00:06:00 CST 2019, time=2019-10-08, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1883907, encodeId=0420188390e14, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Fri Jan 31 07:06:00 CST 2020, time=2020-01-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2055494, encodeId=6d2b2055494ba, content=<a href='/topic/show?id=e6a495203b3' target=_blank style='color:#2F92EE;'>#遗传背景#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95203, encryptionId=e6a495203b3, topicName=遗传背景)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=726030, createdName=Boyinsh, createdTime=Fri Jun 19 19:06:00 CST 2020, time=2020-06-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1546514, encodeId=bc4715465142a, content=<a href='/topic/show?id=81eb2939373' target=_blank style='color:#2F92EE;'>#全基因组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29393, encryptionId=81eb2939373, topicName=全基因组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dc2113925052, createdName=ms1692810954239974, createdTime=Wed Oct 09 12:06:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1610021, encodeId=bfae1610021dd, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=92, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Oct 09 12:06:00 CST 2019, time=2019-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040563, encodeId=82cf1040563cd, content=前列腺癌相关研究,学习了,谢谢梅斯, beContent=null, objectType=article, channel=null, level=null, likeNumber=109, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=misszhang, createdTime=Tue Oct 08 00:06:00 CST 2019, time=2019-10-08, status=1, ipAttribution=)]
    2019-10-08 misszhang

    前列腺癌相关研究,学习了,谢谢梅斯

    0

相关资讯

Eur Urol:前列腺癌发生率和死亡率全球模式分析

之前的研究报道了前列腺癌比例和趋势发生了明显的变化,主要是由于检测、治疗方法和潜在的遗传易感性差异。最近,有研究人员通过更新的发生率和死亡率数据评估了世界范围内前列腺癌的发生率和死亡率情况。研究发现,评估的最高发生率在澳大利亚和新西兰、北美、西欧和北欧以及加勒比地区,发生率最低的在中南亚、北非、东南亚和东亚。评估的死亡率最高在加勒比地区(包括巴巴多斯、特立尼达、多巴哥和古巴)、南非、前苏联部分地区

Sci Rep:精液中的miRNAs可以作为前列腺癌诊断的非侵入性生物标记

尽管对前列腺组织是特异性的,血清前列腺特异性抗原(PSA)筛选经常导致前列腺癌的过度诊断和许多不必要的良性疾病活检,因此需要进一步的改善。最近,有研究人员对PSA水平适度提高的男性的精液的miRNAs表达水平进行了分析,从而评估其作为非侵入性生物标记来对PCa进行诊断和预后的应用价值。研究人员发现,高通量分析表明了PCa患者中miRNA表达模式与健康个体(HCt)相比发生了改变。研究人员考虑了输精

Sci Rep:病灶间的异质性挑战了分子分型在原发性前列腺癌中的临床使用

前列腺癌是高度异质性的疾病,并且在起始诊断时往往具有典型的多个不同的癌症病灶。前列腺癌的分子分型能够游离的辅助精准的诊断和治疗。在癌症基因组数据库(TCGA)中公开了一个很有前景的分型工具,并基于每个患者的癌症样本成功的对74%的原发性前列腺癌分型,共分成了7组。最近,有研究人员探索了该分型工具的临床使用情况,他们在一个多病灶的背景下对该分型工具进行了测试。研究人员共分析了来自于39名患者的85个

Nat Commun:PTEN-ARID4B-PI3K途径鉴定了PTEN缺陷前列腺癌对ARID4B的依赖性

在前列腺癌中,PTEN经常发生变异。PTEN的肿瘤抑制子功能归结于其脂肪磷酸化活性且能够拮抗PI3K的作用。最近,有研究人员报道了PTEN-ARID4B-PI3K途径,其中PTEN能够抑制ARID4B的表达,而ARID4B是PI3K亚单元基因PIK3CA和PIK3R2的转录激活因子,且亚单元基因PIK3CA和PIK3R2对PI3K/AKT途径的激活是非常关键的。ARID4B和组蛋白H1结合到PIK

Eur Urol:男性BRCA1和BRCA2变异位点携带者前列腺癌风险研究

BRCA1和BRCA2变异位点与前列腺癌风险相关,但是大规模的风险评估是基于回顾性的研究。最近,有研究人员评估了BRCA1和BRCA2变异位点的相对和绝对PCa风险,并加入了年龄、家族历史和变异位点来对风险进行修正。研究是一个前瞻性的研究,包括了BRCA1(n=376)和BRCA2(n=447)变异携带者。研究发现,16名BRCA1携带者和26名BRCA2携带者在跟踪调查期间诊断为PCa。BRCA

Ann Oncol:前列腺癌靶向α治疗进展研究

放射性药物治疗方法中,靶向α疗法(TαT)能够实现对癌症细胞和肿瘤微环境有效和局部的选择性放疗,从而以最小的毒性控制癌症恶化。最近,有研究人员讨论了TαT治疗前列腺癌的历史、进展和未来的前景情况,包括了包括剂量学个性化治疗计划、结合小分子疗法以及结合针对前列腺癌细胞表达抗原的分子,如前列腺特异性膜抗原(PSMA)或肿瘤微环境成分。在III阶段ALSYMPCA试验中,已有研究阐释了通过镭-223进行

Baidu
map
Baidu
map
Baidu
map